| Assessment Status | Rapid review complete |
| HTA ID | 20029 |
| Drug | Vedolizumab |
| Brand | Entyvio® |
| Indication | For subcutaneous administration is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or an anti-TNFα. |
| Assessment Process | |
| Rapid review commissioned | 16/06/2020 |
| Rapid review completed | 12/08/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vedolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations October 2021
